Mild cognitive impairment — diagnosis, conversion, and management (MEQ)

(i) Formulation. Working diagnosis: amnestic (likely multi-domain) mild cognitive impairment / mild neurocognitive disorder — objective memory impairment with progressive history, independence largely preserved with compensatory strategies, not meeting major NCD because IADLs remain managed (albeit with checking). Ward MoCA of 22 supports mild impairment but must be interpreted in post-operative context; he is attentive and not fluctuating, reducing likelihood of active delirium now, yet serial outpatient testing is wiser than locking a lifetime label from one post-op score. Differentials: early major NCD if function is under-reported; depression-related cognitive impairment; anticholinergic contribution (oxybutynin); vascular cognitive impairment given diabetes/hypertension; less likely pure normal ageing given objective multi-point deficit and collateral.[1][2][10]

(ii) Work-up and medication review. Collateral-rich history, MSE, functional IADL inventory, mood screen; bloods (B12, folate, TSH, metabolic panel, glucose/HbA1c); structural imaging once if not already done; consider formal neuropsychology after recovery from surgery. Stop or switch oxybutynin (anticholinergic cognitive burden) if urology alternatives exist. Optimise BP/diabetes. Advise against diagnosing from a single post-op screen alone.[6][10]

(iii) Conversion counselling. Elevated risk of progression to dementia compared with age-matched peers — clinic annual conversion often cited around 5–10% per year order of magnitude, setting-dependent (Mitchell meta-analysis). Critically: many remain stable and some revert. Do not promise prevention of Alzheimer disease with a tablet. Explain the independence threshold that would reclassify to major NCD. Offer monitoring plan (e.g. 6–12 months or sooner if decline).[7][6]

(iv) Management and AChEIs. Core: lifestyle and risk-factor care aligned with Lancet Commission and FINGER-style multidomain approaches (exercise, diet quality, cognitive/social engagement, vascular risk, hearing, smoking/alcohol). Treat mood/sleep if present. Do not routinely start donepezil/rivastigmine/galantamine for MCI conversion prevention. Evidence: Petersen 2005 — donepezil transient 12-month signal, not sustained at 36 months, more adverse events; vitamin E ineffective. InDDEx — rivastigmine did not delay AD diagnosis. Cochrane Russ — AChEIs not recommended for MCI. AAN 2018 — may choose not to offer AChEIs; if discussed, full risk-benefit. If function later meets major NCD/AD criteria, revisit dementia pharmacotherapy pathways separately.[3][4][5][6][8][9]